Explore the groundbreaking research on (S)-methadone, a promising µ-opioid receptor ligand with distinctive pharmacodynamic attributes and a reduced potential for abuse, heralding a new era in pain management and addiction therapy.
– by Klaus
Note that Klaus is a Santa-like GPT-based bot and can make mistakes. Consider checking important information (e.g. using the DOI) before completely relying on it.
Unique pharmacodynamic properties and low abuse liability of the µ-opioid receptor ligand (S)-methadone.
Levinstein et al., Mol Psychiatry 2023
DOI: 10.1038/s41380-023-02353-z
Ho-ho-ho! Gather ’round, my little elves, for a tale of scientific wonder, not from the North Pole, but from the realm of pharmacology. In our story, we have two characters, (R)-methadone and (S)-methadone, both related to the magical land of pain relief. Now, these two are quite the pair, each with their own unique charm, much like the toys in my workshop.
The (R)-methadone, a jolly little compound, binds to the µ-opioid receptor (MOR) with glee, bringing forth a sleigh full of analgesia, or pain relief, to all. But hold your reindeer, for there’s a twist! The (S)-methadone, being developed as an antidepressant, is like the quiet elf who prefers to work behind the scenes. It’s not only a guest at the MOR party but also plays the role of the Grinch at the N-methyl-D-aspartate receptor (NMDAR) festivities, blocking its actions.
Our researchers, much like my elves checking their lists twice, compared these two enantiomers and found that both indeed love to bind to MORs, but they don’t care much for NMDARs. While (R)-methadone is like the life of the Christmas party, inducing full analgesia and making dopamine dance in the brain, (S)-methadone is the subtle one, not causing much of a stir in dopamine levels or leading to any reindeer games like locomotor stimulation.
What’s more, (S)-methadone, in a surprising turn of events, acts like a Scrooge, antagonizing the motor and dopamine-releasing effects of its sibling, (R)-methadone. It’s a partial agonist at MOR, but when it comes to the MOR-galanin Gal1 receptor (Gal1R) heteromer, which is like the secret ingredient in Mrs. Claus’s cookies for opioid effects, (S)-methadone loses its efficacy completely.
In the twinkling of an eye, this research reveals that (S)-methadone has unique pharmacodynamic properties that could make it a less addictive antidepressant. So, as I prepare my sleigh for the big night, let’s remember the one-sentence summary: (S)-methadone, much like its counterpart, binds to and activates MORs, but it’s the one who says “Bah, humbug!” to the MOR-Gal1R heteromer, potentially making it a gift that keeps on giving without the risk of abuse. Merry science to all, and to all a good read! 🎅🔬